Loading...
•
Jun 30, 2020
Immunovant Q1 2021 Earnings Report
Reported financial results for the first quarter ended June 30, 2020.
Key Takeaways
Immunovant reported a net loss of $26.7 million for the quarter ended June 30, 2020, and ended the quarter with approximately $280.3 million in cash.
Research and development expenses decreased by $1.6 million compared to the same period in the prior year.
General and administrative expenses increased by $8.1 million compared to the same period in the prior year.
Net loss was $26.7 million, compared to $20.1 million for the same period in the prior year.
The company ended the quarter with approximately $280.3 million in cash.
Forward Guidance
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...